Regencell Bioscience (NASDAQ:RGC) Trading Up 8.9% – Time to Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price shot up 8.9% on Thursday . The stock traded as high as $29.80 and last traded at $29.09. 92,156 shares changed hands during trading, a decline of 87% from the average session volume of 717,375 shares. The stock had previously closed at $26.72.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Regencell Bioscience Stock Up 8.6%

The company’s 50 day moving average price is $26.04 and its 200 day moving average price is $18.46.

Institutional Trading of Regencell Bioscience

Several hedge funds have recently modified their holdings of RGC. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience in the second quarter valued at approximately $1,701,000. Geode Capital Management LLC increased its holdings in Regencell Bioscience by 5,637.5% during the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after purchasing an additional 384,250 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Regencell Bioscience in the 2nd quarter valued at $222,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience in the second quarter worth $768,000. Finally, XTX Topco Ltd acquired a new position in Regencell Bioscience in the third quarter worth $598,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.